Xuan Zhou, PhD, MS

Merck & Co., Inc.

Poster(s):

• 1510 - BELLWAVE-010: An Open-Label, Phase 3 Study of Nemtabrutinib Plus Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma